Business
Cellectar Announces Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2019
Data from an interim evaluation of CLR 131 in relapsed or refractory DLBCL patients will be presented FLORHAM PARK, N.J., Sept. 10, 2019 (GLOBE NEWSWIRE) --
About this update from Cellectar Biosciences, Inc.
[{"type":"text","content":"Data from an interim evaluation of CLR 131 in relapsed or refractory DLBCL patients will be presented\nFLORHAM PARK, N.J., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced an oral presentation at the upcoming European Society for Medical Oncology (ESMO) Congress 2019 being held in Barcelona, Spain from September 27 – October 1, 2019.\n The presentation will focus on the nature of the patient population and the activity of CLR 131 in these heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Presentation details Title:Interim Evaluation of a Targeted Radiotherapeutic, CLR 131, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients (R/R DLBCL)Presenter:Jarrod LongcorSession:Proffered Paper Session – Presentation #1065ODate/Time:September 28, 2019 / 2:45 pm – 3:00 pm CETLocation:Toledo Auditorium (Hall 5), Fira Gran Via, Barcelona, Spain A copy of the presentation materials can be accessed on the Posters and Publications section of the Cellectar website once the presentation concludes. About Cellectar Biosciences, Inc.Cellectar Biosciences is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company is developing proprietary drugs independently and through research and development (R&D) collaborations. The company’s core objective is to leverage its proprietary PDC delivery platform to develop PDCs that specifically target cancer cells, delivering improved efficacy and better safety as a result of fewer off-target effects. The company’s PDC platform possesses the potential for the discovery and development of the next-generation of cancer-targeting treatments, and it plans to develop PDCs independently and through research and development collaborations. The company’s lead PDC therapeutic, CLR 131, is currently in three clinical studies – a Phase 2 study, and two Phase 1 studies. The Phase 2 clinical study (CLOVER-1) is in relapsed/refractory (R/R) B-Cell malignancies, including multiple myeloma (MM), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), lymphoplasmacytic lymphoma (LPL), marginal zone lymphoma (MZL), mantle cell lymph...